TY - JOUR
T1 - Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis
AU - Bossuyt, Xavier
AU - Tervaert, Jan-Willem Cohen
AU - Arimura, Yoshihiro
AU - Blockmans, Daniel
AU - Felipe Flores-Suarez, Luis
AU - Guillevin, Loic
AU - Hellmich, Bernhard
AU - Jennette, J. Charles
AU - Kallenberg, Cees G. M.
AU - Moiseev, Sergey
AU - Novikov, Pavel
AU - Radice, Antonella
AU - Savige, Judith Anne
AU - Sinico, Renato Alberto
AU - Specks, Ulrich
AU - van Paassen, Pieter
AU - Zhao, Ming-hui
AU - Rasmussen, Niels
AU - Damoiseaux, Jan
AU - Csernok, Elena
AU - Jayne, David
PY - 2017/11
Y1 - 2017/11
N2 - Anti-neutrophil cytoplasmic antibodies (ANCAs) are valuable laboratory markers used for the diagnosis of well-defined types of small-vessel vasculitis, including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). According to the 1999 international consensus on ANCA testing, indirect immunofluorescence (IIF) should be used to screen for ANCAs, and samples containing ANCAs should then be tested by immunoassays for proteinase 3 (PR3)-ANCAs and myeloperoxidase (MPO)-ANCAs. The distinction between PR3-ANCAs and MPO-ANCAs has important clinical and pathogenic implications. As dependable immunoassays for PR3-ANCAs and MPO-ANCAs have become broadly available, there is increasing international agreement that high-quality immunoassays are the preferred screening method for the diagnosis of ANCA-associated vasculitis. The present Consensus Statement proposes that high-quality immunoassays can be used as the primary screening method for patients suspected of having the ANCA-associated vaculitides GPA and MPA without the categorical need for IIF, and presents and discusses evidence to support this recommendation.
AB - Anti-neutrophil cytoplasmic antibodies (ANCAs) are valuable laboratory markers used for the diagnosis of well-defined types of small-vessel vasculitis, including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). According to the 1999 international consensus on ANCA testing, indirect immunofluorescence (IIF) should be used to screen for ANCAs, and samples containing ANCAs should then be tested by immunoassays for proteinase 3 (PR3)-ANCAs and myeloperoxidase (MPO)-ANCAs. The distinction between PR3-ANCAs and MPO-ANCAs has important clinical and pathogenic implications. As dependable immunoassays for PR3-ANCAs and MPO-ANCAs have become broadly available, there is increasing international agreement that high-quality immunoassays are the preferred screening method for the diagnosis of ANCA-associated vasculitis. The present Consensus Statement proposes that high-quality immunoassays can be used as the primary screening method for patients suspected of having the ANCA-associated vaculitides GPA and MPA without the categorical need for IIF, and presents and discusses evidence to support this recommendation.
KW - ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES
KW - INFLAMMATORY-BOWEL-DISEASE
KW - SMALL-VESSEL VASCULITIS
KW - LINKED-IMMUNOSORBENT-ASSAY
KW - RHEUMATOLOGY 1990 CRITERIA
KW - ANTI-MPO ANTIBODIES
KW - WEGENERS-GRANULOMATOSIS
KW - SYSTEMIC VASCULITIS
KW - FOLLOW-UP
KW - INDIRECT IMMUNOFLUORESCENCE
U2 - 10.1038/nrrheum.2017.140
DO - 10.1038/nrrheum.2017.140
M3 - Article
C2 - 28905856
SN - 1759-4790
VL - 13
SP - 683
EP - 692
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
IS - 11
ER -